Skip to search formSkip to main contentSkip to account menu

HER2/Neu/cerbB2 Antagonists [MoA]

Known as: HER-2/Neu/cerbB2 Antagonists, HER2 Inhibitors, HER-2 Inhibitors 
National Institutes of Health

Related topics

Related topics

4 relations
14 ML pertuzumab 30 MG/ML Injectionado-trastuzumab emtansinepertuzumabtrastuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Targeting HER2+ breast cancer: the TBK1/IKKε axis
HER2+ breast cancer (BC) is a highly aggressive subtype, affecting ~20% of BC patients. Current treatments include adjuvant or… 
2013
2013
Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.
INTRODUCTION Gemcitabine is a pyrimidine nucleoside analog that becomes triphosphorylated and competitively inhibits cytidine… 
2013
2013
Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3…
Aims Delineate the feasibility of simultaneous, dual selective “targeted” chemotherapeutic delivery and determine if this… 
2011
2011
Prognostic significance of HER2/neu expression in gastric cancer
ZusammenfassungHINTERGRUND: Das Magenkarzinom ist in vielen Ländern noch immer die häufigste Neoplasie. Deshalb werden neben den… 
2010
2010
[Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
OBJECTIVE To investigate the expression of HER2/neu, Ki-67 and TK1 protein in meningiomas in correlation with tumor grades and… 
Review
2010
Review
2010
HER2/neu Immunostaining in Invasive Breast Cancer: Analysis of False Positive Factors.
OBJECTIVES HER2/neu gene amplification by Fluorescent in situ hybridization and protein expression by immunohistochemistry have… 
2009
2009
Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition
Immunoconjugates of epirubicin were synthesized with monoclonal antibodies against the epidermal growth factor receptors, HER2… 
2008
2008
CUP-Syndrom
ZusammenfassungUnter „Cancer-of-unknown-primary-Syndrom“, kurz CUP-Syndrom, werden diejenigen Tumorerkrankungen zusammengefasst… 
2002
2002
Molekulare Pathogenese des Endometriumkarzinoms auf Basis eines dualistischen Modells
In biologischer und klinischer Hinsicht unterscheidet man 2 unterschiedliche Typen des Endometriumkarzinoms, von denen einer… 
Review
1995
Review
1995
Regulation of her2/neu gene-expression (review).
Transcriptional regulation of the HER2/neu protooncogene (also known as c-erbB2) has been the topic of many recent reports. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)